Efficacy of preoperative trimetazidine for preventing myocardial injury in patients undergoing off-pump coronary artery bypass grafting

Yıl 2016, Cilt: 2 Sayı: 2, 107 - 111, 04.07.2016

Tamer Turk Yusuf Ata Ufuk Aydin Hasan Ari Kagan Ahmet As Senol Yavuz

https://doi.org/10.18621/eurj.2016.5000183532

Öz

Objective. Off-pump coronary artery bypass grafting (CABG) with median sternotomy have been shown to be beneficial and associated with reduced myocardial injury. However, there is still a risk for ischemic myocardial injury that results from the normothermic  and metabolically active myocardium during the occlusion of the target coronary artery. We aimed to evaluate the efficacy of trimetazidine in prevention of myocardial tissue injury in patients undergoing off-pump CABG by measuring serum levels of cardiac troponin I (cTnI). Methods. Thirty patients undergoing first-time elective off-pump CABG were randomly assigned to two groups: 15 patients received trimetazidine 60 mg orally per day (trimetazidine group) for three weeks and 15 patients received placebo (control group).  As a parameter of myocardial injury, we measured cTnI levels. Blood samples were taken sequentially from the patients before surgery (t1), 30 minutes after the last distal anastomosis (t2), at postoperative 12^th hour (t3) and at postoperative 24^th hour (t4). cTnI measurements were made by direct chemiluminometric technology. Results. Baseline and operative characteristics of patients are similar.  All preoperative serum cTnI concentrations were within the normal range and rose with the beginning of the operation which reached to its peak value at t3 in the control group and t4 in trimetazidine group. When the increase in the serum cTnI concentrations of trimetazidine group and control group were compared there was a slight numerical increase in cTnI levels in all measurements after reperfusion but reached to statistical significance only at t3 (mean: 0.40 ng/ml; mean rank: 12.20; range: 0.05-1.66 vs. mean: 0.20 ng/ml; mean rank: 18.80; range: 0.11-0.30; p=0.041). Conclusion. Preoperative treatment with trimetazidine might reduce postoperative myocardial injury in patients undergoing first time isolated off-pump CABG, but larger randomized placebo controlled trials are still for recommendation of routine pretreatment with trimetazidine.   

Anahtar Kelimeler

Off-pump CABG, trimetazidine, troponin I

Kaynakça

• Tunerir B, Colak O, Alatas O, Besogul Y, Kural T, Aslan R. Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann Thorac Surg 1999;68:2173-2176.
• Czerny M, Baumer H, Kilo J, Lassnigg A, Hamwi A, Vukovich T, et al. Inflammatory response and myocardial injury following coronary artery bypass grafting with or without cardiopulmonary bypass. Eur J Cardiothorac Surg 2000;17:737-742.
• Turk T, Ata Y, Vural H, Tiryakioglu O, Eris C, Yavuz S. Evaluation of myocardial injury by serum levels of creatine kinase MB, myoglobin, and cardiac troponin I following off-pump and on-pump coronary artery bypass. Turk Gogus Kalp Dama 2005;13:224-228.
• Tasdemir O, Vural KM, Karagoz H, Bayazit K. Coronary artery bypass grafting on the beating heart without the use of extracorporeal circulation: review of 2052 cases. J Thorac Cardiovasc Surg 1998;116:68-73.
• Yavuz S, Celkan MA, Eris C, Mavi M, Turk T, Tiryakioglu O, et al. Minimally invasive coronary artery bypass: experience in 114 patients. Asian Cardiovasc Thorac Ann 1999;7:177-181.
• Banach M, Goch A, Rysz C, Ugurlucan M, Mikhailidis DP, Goch JA. The role of trimetazidine in patients subjected to surgical revascularization. Arc Med Sci 2007;3:52-56.
• Banach M, Rysz J, Goch A, Mikhailidis DP, Rosano GM. The role of trimetazidine after acute myocardial infarction. Curr Vasc Pharmacol 2008;6:282-291.
• Zhang N, Lei J, Liu Q, Huang W, Xiao H, Lei H. The effectiveness of preoperative trimetazidine on myocardial preservation in coronary artery bypass graft patients: a systematic review and meta-analysis. Cardiology 2015;131:86-96.
• Argaud L, Gomez L, Gateau-Roesch O, Couture-Lepetit E, Loufouat J, Robert D, et al. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol 2005;39:893-899.
• Ruixing Y, Wenwu L, Al-Ghazali R. Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemia-reperfusion. Transl Res 2007;149:152-160.
• Vermes E, Mesguich M, Houel R, Soustelle C, Le Besnerais P, Hillion ML, et al. Cardiac troponin I release after open heart surgery: a marker of myocardial protection? Ann Thorac Surg 2000;70:2087-2090.
• Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury.CMAJ 2005;173:1191-1202.
• Jacquet L, Noirhomme P, El Khoury G, Goenen M, Philippe M, Col J, et al. Cardiac troponin I as an early marker of myocardial damage after coronary bypass surgery. Eur J Cardiothorac Surg 1998;13:378-384.
• Kilger E, Pichler B, Weis F, Goetz A, Lamm P, Schutz A, et al. Markers of myocardial ischemia after minimally invasive and conventional coronary operation. Ann Thorac Surg 2000;70:2023-2028.
• Wan S, Izzat MB, Lee TW, Wan IY, Tang NL, Yim AP. Avoiding cardiopulmonary bypass in multivessel CABG reduces cytokine response and myocardial injury. Ann Thorac Surg 1999;68:52-56.
• Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-969.